FLAME 2020
Therapies and Diagnostics for Uterine Cancer
Report Highlights
The global market for uterine cancer treatments and diagnostics reached $17.4 billion in 2012. This market is expected to grow to nearly $17.8 billion in 2013 and then to nearly $21.6 billion in 2018, a compound annual growth rate (CAGR) of 3.9% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the global market for diagnostics and therapies for uterine cancer
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- A breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy
- Discussion of uterine cancer biology
- Delineation of drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic
- Evaluation of the patent landscape
- Comprehensive profiles of key companies.
SCOPE OF THE STUDY
The scope of this study is diagnostic test and therapeutic markets for uterine cancers. Screening tests are included as discussion only, as new studies have reflected that Pap smears, CT scans and ultrasound could be used as screening aids for uterine cancer. The exact usage for these tests for uterine cancer is still under research; therefore, sales numbers and revenue forecasts from this segment are not included in the final market summary. The focus of this report is on diagnostic tests and therapeutics for uterine cancer, including surgery and diagnostic methods (e.g., hysteroscopy and endometrial biopsy) that are currently in use. The report also includes discussions on the current technologies, new technologies, incidence, market projections and market share, along with the latest trends and new developments.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.